Pathos Email Format
Biotechnology ResearchNew York, United States51-200 Employees
Pathos is a clinical-stage biotechnology company based in New York, New York, focused on oncology and powered by artificial intelligence. It aims to accelerate cancer drug development by integrating AI with multimodal patient data to reduce reliance on guesswork, guiding both biological validation and biomarker-driven clinical execution. The company centers its approach on an oncology-focused multimodal foundation model that underpins an integrated discovery engine. It operates within biotechnology research and collaborates with pharmaceutical and data partners to advance cancer therapies. In May 2026 Pathos Lab announced the acquisition of a majority stake in DeuterOncology, a Belgium-based company developing DO-2, a third-generation MET kinase inhibitor for MET-altered cancers.